ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Macquarie Upgrades ResMed (RMD) to Neutral
April 28, 2016 7:08 AM EDTMacquarie upgraded ResMed (NYSE: RMD) from Underperform to Neutral.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $56.65 yesterday.
... MorePiper Jaffray Downgrades ResMed (RMD) to Neutral
April 27, 2016 6:37 AM EDTPiper Jaffray downgraded ResMed (NYSE: RMD) from Overweight to Neutral with a price target of $57.00 (from $65.00).
Analyst Matt O'Brien commented, "We are downgrading RMD to Neutral from Overweight and lowering our PT to $57 from $65. The genesis of our downgrade is that we believe headwinds and the lack of near term... More
ResMed (RMD) Misses Q3 EPS by 1c
April 26, 2016 4:14 PM EDTResMed (NYSE: RMD) reported Q3 EPS of $0.68, $0.01 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $453.9 million versus the consensus estimate of $455.88 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More